Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVORY: Low-dose interleukin-2 in acute coronary syndromes
2017-005130-27Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina comparing Low-dose aldesleukin with Placebo (2 arms). Primary endpoint: Change in vascular inflammation in index vessel. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on 2017-005130-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005130-27.